26,995 Shares in Insmed Incorporated (NASDAQ:INSM) Bought by Proficio Capital Partners LLC

Proficio Capital Partners LLC acquired a new stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 26,995 shares of the biopharmaceutical company's stock, valued at approximately $1,864,000.

Several other large investors also recently bought and sold shares of the business. Geode Capital Management LLC grew its stake in Insmed by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company's stock valued at $278,432,000 after acquiring an additional 172,664 shares in the last quarter. Principal Financial Group Inc. grew its stake in Insmed by 12.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company's stock valued at $136,648,000 after acquiring an additional 214,130 shares in the last quarter. Vestal Point Capital LP grew its stake in shares of Insmed by 113.3% in the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock valued at $116,800,000 after buying an additional 850,000 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Insmed by 7.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,546,607 shares of the biopharmaceutical company's stock valued at $106,778,000 after buying an additional 102,341 shares during the period. Finally, Wellington Management Group LLP grew its stake in shares of Insmed by 2.6% in the 3rd quarter. Wellington Management Group LLP now owns 962,459 shares of the biopharmaceutical company's stock valued at $70,260,000 after buying an additional 24,025 shares during the period.

Remove Ads

Insiders Place Their Bets

In other news, CFO Sara Bonstein sold 18,322 shares of the firm's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $80.31, for a total value of $1,471,439.82. Following the sale, the chief financial officer now directly owns 118,863 shares in the company, valued at approximately $9,545,887.53. This trade represents a 13.36 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 18,750 shares of the firm's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $77.03, for a total transaction of $1,444,312.50. Following the completion of the sale, the chief executive officer now owns 334,186 shares in the company, valued at $25,742,347.58. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 550,957 shares of company stock worth $42,992,528 in the last ninety days. 4.60% of the stock is owned by corporate insiders.

Insmed Stock Up 1.5 %

Insmed stock traded up $1.15 during mid-day trading on Friday, reaching $79.92. 1,928,336 shares of the company's stock were exchanged, compared to its average volume of 2,182,816. The company has a market cap of $14.47 billion, a P/E ratio of -14.30 and a beta of 1.28. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. The company has a fifty day moving average of $77.43 and a 200-day moving average of $73.80.

Insmed (NASDAQ:INSM - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Sell-side analysts expect that Insmed Incorporated will post -4.56 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on INSM. HC Wainwright reissued a "buy" rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, February 21st. Wells Fargo & Company increased their price target on shares of Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research note on Wednesday, February 19th. JPMorgan Chase & Co. increased their price target on shares of Insmed from $83.00 to $92.00 and gave the company an "overweight" rating in a research note on Friday, February 7th. Royal Bank of Canada reissued an "outperform" rating and issued a $100.00 price target on shares of Insmed in a research note on Wednesday. Finally, Morgan Stanley increased their price target on shares of Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $94.00.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.